Physician profile
David A Wilt
NPI 1508857509
$13,082.65
in general payments reported to CMS, 2019-2025
67 companies · $35.79 in 2025
The $35.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $1,438 · 2021: $2,962 · 2022: $2,454 · 2023: $2,872 · 2024: $2,060 · 2025: $35.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,967.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.35 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,319.22 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,301.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,215.68 | 2019-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,125.14 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $544.01 | 2019-2024 | |
| Amarin Pharma, INC. | $529.95 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $450.12 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $376.36 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $357.22 | 2019-2023 | Belsomra, Steglatro |
| Eisai INC. | $290.84 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.12 | 2021-2024 | |
| Dexcom, INC. | $231.73 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.57 | 2020-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $159.78 | 2020-2024 | Recorlev, Keveyis |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.